Resapp Health (RAP.AX) Stock Price

Resapp Health Price

🇦🇺CLOSED
0.04AUD
Market closed
Today +/-
Today %

Resapp Health (RAP.AX) Stock | ISIN AU000000RAP5. The current Resapp Health stock price is 0.04 AUD (2026). Market capitalization is 32.65 M AUD. Resapp Health operates in the Health sector.

Revenue has compounded at 16.1% per year over the past 17 years to 2.51 M AUD. Resapp Health's net margin stands at -282.1%, up from -7,509.7% several years earlier.

Resapp Health stock price

Details

Stock Price

How to Read This Chart

This chart tracks the historical stock price of Resapp Health over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.

Total Return vs. Price Return

The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.

Intraday Price Data

When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how Resapp Health stock reacts to market openings, earnings releases, or breaking news throughout the trading session.

What to Look For

Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing Resapp Health's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.

Resapp Health Stock Price History
DateResapp Health Price
Access this data via the Eulerpool API

Resapp Health Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2004
0 AUD
-830,000 AUD
-1.18 M AUD
Jan 1, 2005
200,000 AUD
-680,000 AUD
-710,000 AUD
Jan 1, 2006
420,000 AUD
-2.15 M AUD
-1.82 M AUD
Jan 1, 2007
1.41 M AUD
-3.92 M AUD
-3.67 M AUD
Jan 1, 2008
0 AUD
-1.23 M AUD
-3.59 M AUD
Jan 1, 2009
0 AUD
-970,000 AUD
-1.2 M AUD
Jan 1, 2010
850,000 AUD
210,000 AUD
220,000 AUD
Jan 1, 2011
80,000 AUD
-390,000 AUD
-530,000 AUD
Jan 1, 2012
60,000 AUD
-830,000 AUD
-830,000 AUD
Jan 1, 2013
20,000 AUD
-920,000 AUD
-920,000 AUD
Jan 1, 2014
0 AUD
-470,000 AUD
-580,000 AUD
Jan 1, 2015
173,400 AUD
-488,700 AUD
-489,300 AUD
Jan 1, 2016
82,600 AUD
-3.2 M AUD
-3.21 M AUD
Jan 1, 2017
204,300 AUD
-10.03 M AUD
-10.03 M AUD
Jan 1, 2018
87,000 AUD
-6.53 M AUD
-6.53 M AUD

Resapp Health Income Statement, Balance Sheet, Cash Flow Statement

Last updated Jun 23, 2026, 6:29 AM
 
REVENUE (M AUD)
REVENUE GROWTH (%)
GROSS MARGIN (%)
GROSS INCOME (M AUD)
NET INCOME (M AUD)
NET INCOME GROWTH (%)
SHARES (M)
DOCUMENTS
201820192020202120222023e2024e2025e
00002163785
700131.25129.73
----
00000000
-6-5-8-6-7000
-40-16.6760-2516.67
659.04685.19707.79778.3859.22859.22859.22859.22
Details

Income Statement Key Figures

Revenue and Revenue Growth

Revenue is the starting point of every income statement — it measures the total sales Resapp Health generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.

Gross Margin

Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue Resapp Health retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare Resapp Health's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.

EBIT and EBIT Margin

EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.

Net Income and Earnings Per Share (EPS)

Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.

Shares Outstanding

The total number of shares Resapp Health has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.

Analyst Estimates

The projected figures represent consensus estimates from professional analysts. Compare these forecasts against Resapp Health's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.

Resapp Health stock margins

The Resapp Health margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Resapp Health. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Resapp Health.
  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2004
39.01 %
- %
- %
Jan 1, 2005
15 %
-340 %
-355 %
Jan 1, 2006
64.29 %
-511.9 %
-433.33 %
Jan 1, 2007
39.01 %
-278.01 %
-260.28 %
Jan 1, 2008
39.01 %
- %
- %
Jan 1, 2009
39.01 %
- %
- %
Jan 1, 2010
39.01 %
24.71 %
25.88 %
Jan 1, 2011
39.01 %
-487.5 %
-662.5 %
Jan 1, 2012
39.01 %
-1,383.33 %
-1,383.33 %
Jan 1, 2013
39.01 %
-4,600 %
-4,600 %
Jan 1, 2014
39.01 %
- %
- %
Jan 1, 2015
39.01 %
-281.83 %
-282.18 %
Jan 1, 2016
39.01 %
-3,880.02 %
-3,883.29 %
Jan 1, 2017
39.01 %
-4,908.42 %
-4,910.82 %
Jan 1, 2018
39.01 %
-7,504.94 %
-7,509.66 %

Resapp Health Stock Revenue, EBIT, Earnings per Share

The Resapp Health earnings per share therefore indicates how much revenue Resapp Health has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.
  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue per Share
EBIT per share
Earnings per Share
Details
Date
Revenue per Share
EBIT per share
Earnings per Share
Jan 1, 2004
0 AUD
-0.01 AUD
-0.01 AUD
Jan 1, 2005
0 AUD
-0.01 AUD
-0.01 AUD
Jan 1, 2006
0 AUD
-0.01 AUD
-0.01 AUD
Jan 1, 2007
0.01 AUD
-0.02 AUD
-0.02 AUD
Jan 1, 2008
0 AUD
-0.01 AUD
-0.02 AUD
Jan 1, 2009
0 AUD
-0 AUD
-0.01 AUD
Jan 1, 2010
0 AUD
0 AUD
0 AUD
Jan 1, 2011
0 AUD
-0 AUD
-0 AUD
Jan 1, 2012
0 AUD
-0 AUD
-0 AUD
Jan 1, 2013
0 AUD
-0 AUD
-0 AUD
Jan 1, 2014
0 AUD
-0 AUD
-0 AUD
Jan 1, 2015
0 AUD
-0 AUD
-0 AUD
Jan 1, 2016
0 AUD
-0.01 AUD
-0.01 AUD
Jan 1, 2017
0 AUD
-0.02 AUD
-0.02 AUD
Jan 1, 2018
0 AUD
-0.01 AUD
-0.01 AUD

Resapp Health business model & stock analysis

ResApp Health Ltd is an Australian company that focuses on the development of digital diagnostic and treatment solutions in the field of respiratory diseases. The company was founded in 2014 by Tony Keating and Philippa Lewis, both of whom have significant experience in the medical technology industry. The company aims to improve and simplify the diagnosis of respiratory diseases by developing a diagnosis based on cough and breath sounds. To achieve this, the company has developed an intelligent system based on machine learning and artificial intelligence that analyzes individual sound waves and provides an accurate diagnostic capability. ResApp Health's business model is based on the development of digital diagnostic and treatment solutions in the field of respiratory diseases, which are offered through various distribution channels. The company offers both mobile apps and clinical diagnostic systems. ResApp Health operates in various divisions at different levels. On the one hand, the company conducts research and development to continuously improve its products. On the other hand, it works closely with clinicians, scientists, and other industry experts to enable the best possible patient treatment. Products offered by ResApp Health include digital diagnostic systems in the field of respiratory diseases that function based on cough and breath sounds. The products are offered for use in both clinical practice and at home to enable fast and accurate diagnosis. Another important area in which ResApp Health operates is the treatment of respiratory diseases. The company offers digital therapy platforms tailored to the individual needs of patients, enabling improved therapy. ResApp Health has already achieved a number of important milestones. For example, in 2016, the company received CE marking for its digital diagnostic system, and in 2017, it completed a clinical study that demonstrated the system's high accuracy in diagnosing respiratory diseases. Overall, ResApp Health has great potential to play an important role in the field of diagnosis and treatment of respiratory diseases in the future. With a strong focus on research and development and close collaboration with industry experts, the company will continue to offer innovative solutions to improve patient health.

Resapp Health SWOT Analysis

Strengths

Resapp Health Ltd possesses several strengths that contribute to its success in the healthcare industry. Firstly, the company's proprietary technology offers a non-invasive and convenient solution for diagnosing respiratory conditions. This provides a competitive advantage over traditional diagnostic methods.

Furthermore, Resapp Health Ltd has a strong intellectual property portfolio, protecting their innovative technology and ensuring differentiation from competitors. This allows them to capitalize on their unique offering and maintain a strong market position.

Weaknesses

Despite its strengths, Resapp Health Ltd also faces certain weaknesses that need to be addressed for sustainable growth. One such weakness is the company's heavy reliance on partnerships and collaborations for commercialization and market penetration. This dependence exposes the company to potential risks, such as partnership failures or delays in product development.

Additionally, Resapp Health Ltd has limited financial resources compared to larger competitors in the industry. This could constrain their ability to invest in research and development, marketing efforts, and expanding their operations, potentially limiting their growth potential.

Opportunities

Resapp Health Ltd operates in a rapidly growing digital health market, which presents various opportunities for future success. The increasing adoption of telehealth services and remote patient monitoring creates a favorable market environment for the company's respiratory diagnostic solutions. By positioning themselves as a leader in this space, Resapp Health Ltd can capitalize on the growing demand for convenient and accurate healthcare solutions.

Furthermore, expanding their product offerings to cover other respiratory conditions and diseases opens up new avenues for revenue growth for Resapp Health Ltd. This diversification can help mitigate market risks and increase their market share.

Threats

Resapp Health Ltd faces several potential threats within the healthcare industry. One significant threat is the high level of competition from both established players and emerging start-ups with similar respiratory diagnostic solutions. These competitors may have greater financial resources, larger customer bases, or stronger brand recognition, posing a challenge to Resapp Health Ltd's market position.

Another threat is the ever-changing regulatory landscape in the healthcare industry. Compliance with evolving regulations and obtaining necessary approvals can be resource-intensive and time-consuming for Resapp Health Ltd. Failure to comply with regulatory requirements could result in delays or restrictions in product commercialization.

Resapp Health Eulerpool Fair Value

Resapp Health historical P/E ratio, EBIT multiple, and P/S ratio

Resapp Health annual returns

Details

Annual Return

What This Chart Shows

This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.

Price Return

Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.

Dividend Return

Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.

What to Look For

Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.

Resapp Health shares outstanding

The number of shares was Resapp Health in 2025 — This indicates how many shares 859.218 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.
  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Number of stocks
Details
Date
Number of stocks
Jan 1, 2004
85.52 M base_Shares
Jan 1, 2005
124.37 M base_Shares
Jan 1, 2006
161.38 M base_Shares
Jan 1, 2007
164.57 M base_Shares
Jan 1, 2008
196.67 M base_Shares
Jan 1, 2009
196.67 M base_Shares
Jan 1, 2010
196.67 M base_Shares
Jan 1, 2011
235.6 M base_Shares
Jan 1, 2012
430.12 M base_Shares
Jan 1, 2013
430.12 M base_Shares
Jan 1, 2014
458.99 M base_Shares
Jan 1, 2015
205.33 M base_Shares
Jan 1, 2016
491.71 M base_Shares
Jan 1, 2017
655.48 M base_Shares
Jan 1, 2018
659.04 M base_Shares
Price targets and forecasts for Resapp Health are not yet available.

Resapp Health shareholder structure

% Name
4.1724%
Freeman Road Pty. Ltd.
Freeman Road Pty. Ltd.
2.29857%
Sunreef Pty. Ltd.
Sunreef Pty. Ltd.
1.89451%
Chew (Weng Thong Frank)
Chew (Weng Thong Frank)
1.19004%
Keating (Anthony James)
Keating (Anthony James)
1.04746%
Evolution Capital Advisors Pty. Ltd.
Evolution Capital Advisors Pty. Ltd.
1.01575%
Aston (Roger)
Aston (Roger)
0.93073%
Narhex Life Sciences Developments Ltd.
Narhex Life Sciences Developments Ltd.
0.91361%
CEM International (Asia) Pty. Ltd.
CEM International (Asia) Pty. Ltd.
0.82281%
Peng (Yongsheng)
Peng (Yongsheng)
0.68698%
Leedman (Brian)
Leedman (Brian)

Resapp Health Executives and Management Board

DM

David Mandel

Director · since 2009

Compensation28,260 AUD
RA

Dr. Roger Aston

Non-Executive Chairman of the Board

MC

Mr. Mike Connell

Vice President - Commercial

BL

Mr. Brian Leedman

Executive Director · since 2016

NF

Ms. Nicki Farley

Company Secretary · since 2012

Resapp Health Supply Chain

Frequently asked questions about Resapp Health

Resapp Health Ltd is a medical technology company that specializes in the development of innovative respiratory diagnostic and management solutions. Their business model revolves around designing and commercializing smartphone-based applications, algorithms, and software solutions for the diagnosis and management of respiratory conditions. By utilizing the power of artificial intelligence and machine learning, Resapp Health Ltd aims to provide accurate, accessible, and cost-effective respiratory healthcare to patients worldwide. With a focus on improving respiratory disease outcomes, their technologies have the potential to revolutionize the way respiratory conditions are diagnosed and managed, ultimately leading to better patient outcomes and reduced healthcare costs.

All fundamentals and in-depth analysis of Resapp Health

Our stock analysis for Resapp Health Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Resapp Health Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.